Jacobs & Co. CA Sells 3,836 Shares of GSK plc (NYSE:GSK)

Jacobs & Co. CA reduced its stake in shares of GSK plc (NYSE:GSK) by 2.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 150,149 shares of the pharmaceutical company’s stock after selling 3,836 shares during the period. Jacobs & Co. CA’s holdings in GSK were worth $5,564,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in GSK. Versant Capital Management Inc lifted its stake in GSK by 2,816.7% in the fourth quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock worth $26,000 after purchasing an additional 676 shares during the last quarter. Fairfield Bush & CO. bought a new stake in GSK in the second quarter worth $28,000. BKM Wealth Management LLC bought a new stake in GSK in the fourth quarter worth $32,000. Larson Financial Group LLC lifted its stake in GSK by 271.8% in the third quarter. Larson Financial Group LLC now owns 885 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 647 shares during the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its stake in GSK by 61.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 968 shares of the pharmaceutical company’s stock worth $42,000 after purchasing an additional 368 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. Citigroup upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. Morgan Stanley initiated coverage on shares of GSK in a research report on Tuesday, January 23rd. They set an “equal weight” rating on the stock. Finally, Jefferies Financial Group upgraded shares of GSK from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

GSK Price Performance

Shares of NYSE GSK opened at $43.00 on Thursday. GSK plc has a 1 year low of $33.33 and a 1 year high of $43.84. The company has a debt-to-equity ratio of 1.19, a current ratio of 0.88 and a quick ratio of 0.62. The company’s 50-day moving average is $41.56 and its 200 day moving average is $38.32. The stock has a market capitalization of $88.50 billion, a P/E ratio of 14.28, a P/E/G ratio of 1.94 and a beta of 0.64.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). The business had revenue of $10 billion during the quarter, compared to analysts’ expectations of $9.79 billion. GSK had a return on equity of 51.45% and a net margin of 16.24%. On average, sell-side analysts expect that GSK plc will post 4.07 earnings per share for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 11th. Shareholders of record on Friday, February 23rd will be issued a $0.3564 dividend. This represents a $1.43 dividend on an annualized basis and a yield of 3.32%. The ex-dividend date is Thursday, February 22nd. This is a boost from GSK’s previous quarterly dividend of $0.34. GSK’s dividend payout ratio is 52.82%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.